


**Human testis staining:** Incubation of testis slides with our human **anti-DTM mAb** followed by secondary alkaline phosphatase-conjugated IgG antibody staining. Based on the 73% homology between mouse and human DTM, the same antibody can be used in mouse.




**anti-Piwil2**

mAb clone 87/3, IgM  
immunogen: human Piwil-2 peptide  
(MDPFRPSFRGQSPIHPSQCQAVRMPG)

Balb/c mouse  
fusion partner: X63Ag8.653 myeloma cells

Reactivity: MDP peptide (ELISA, see figure) human Piwil-2 (immunohistochemistry; further testing in progress)



## Licensing Opportunity

# Monoclonal PIWIL2 Antibodies

Scientists at the University of Göttingen generated monoclonal and polyclonal antibodies against the new **diagnostic tumor marker (DTM) PIWIL2**. PIWIL2 is not present in normal cells (other than testicular), not present in inflammatory tissues but present in almost all **cancer cell types**. Because of its important role in **tumor genesis** and therefore early detection of tumors it could be used for **first line screening** and as a **therapeutic target**. The world market for cancer diagnosis is estimated to be 3.5 billion dollars for 2010.

### Hallmarks

- Tested in tissues and in blood (from patients)
- Established use of monoclonal antibody for tissues and smears
- Analysis at protein and gene expression level (RT-PCR, ELISA, mAb)
- **In development:**
- Detection of DTM protein in blood samples by ELISA using our human monoclonal antibody.
- Analysis of a wide range of human normal and tumor tissues with our mAb
- Analysis of different tumor growth stages.

We are looking for companies, who are interested in **licensing** these antibodies for selling them to industrial and scientific institutions or for developing advanced **diagnostic tests** and **therapeutic solutions**.